Evidence map›Paper›PMID 39505357›Full record

ArticleMolecular pharmaceutics2024

DeepCt: Predicting Pharmacokinetic Concentration-Time Curves and Compartmental Models from Chemical Structure Using Deep Learning.

Maximilian Beckers, Dimitar Yonchev, Sandrine Desrayaud, Grégori Gerebtzoff, Raquel Rodríguez-Pérez

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maximilian BeckersBiomedical Research, Novartis Pharma AG, Novartis Campus, 4002 Basel, Switzerland.ORCID 0000-0001-5988-1322
Dimitar YonchevBiomedical Research, Novartis Pharma AG, Novartis Campus, 4002 Basel, Switzerland.
Sandrine DesrayaudBiomedical Research, Novartis Pharma AG, Novartis Campus, 4002 Basel, Switzerland.
Grégori GerebtzoffBiomedical Research, Novartis Pharma AG, Novartis Campus, 4002 Basel, Switzerland.
Raquel Rodríguez-PérezBiomedical Research, Novartis Pharma AG, Novartis Campus, 4002 Basel, Switzerland.ORCID 0000-0002-2992-3402

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After initial triaging using in vitro absorption, distribution, metabolism, and excretion (ADME) assays, pharmacokinetic (PK) studies are the first application of promising drug candidates in living mammals. Preclinical PK studies characterize the evolution of the compound's concentration over time, typically in rodents' blood or plasma. From this concentration-time (

Indexed as

Deep LearningPharmacokineticsAnimalsHumansModels, BiologicalPharmaceutical PreparationsPharmaceutical Preparationscompartmental analysisconcentration−timedeep learningdrug discoverymachine learningmechanistic modelingpharmacokineticstime-exposure

Identifiers

PMID39505357
PMCPMC11615940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.